Pipeline Regulation

Weekly R&D and Compliance Ledger: Hengrui's 81% liver-fat drop meets Guangxi dual probes

China Pharma Desk's Nov 21, 2026 ledger covers Hengrui's (600276.SS) 81.0% AASLD liver-fat drop on HRS-4729 (NCT06762600) and herombopag sNDA (CXHS2600158), GenSci161, and CSRC/FDA probes in Guangxi.

Weekly R&D and Compliance Ledger: Hengrui's 81% liver-fat drop meets Guangxi dual probes
China Pharma Desk synthesis of CNINFO statutory filings (November 18–21, 2026), AASLD 2026 oral presentation (NCT06762600), CSRC Guangxi Bureau Warning Letter [2026] No. 23, and U.S. FDA Form 483 inspection records.

Between November 18 and November 21, 2026, domestic statutory filings on CNINFO, clinical readouts from the 77th American Association for the Study of Liver Diseases (AASLD) Annual Meeting, and newly released U.S. and Chinese regulatory enforcement notices converged across two distinct tracks. On the R&D front, six Chinese drugmakers—led by Jiangsu Hengrui Pharmaceuticals (SSE: 600276; HKEX: 01276), Changchun High-Tech / GenSci (SZSE: 000661), Huadong Medicine (SZSE: 000963), Hybio Pharmaceutical (SZSE: 300199), Simcere Pharmaceutical (HKEX: 02096), and Shenyang Xingqi Ophthalmic (SZSE: 300573)—advanced multi-target biologics, PROTAC degraders, and GLP-1/GIP/GCG triple agonists across metabolic liver disease and rare autoinflammatory disorders. Over the same 48-hour window, two flagship pharmaceutical groups in Guangxi Province were hit by severe domestic and U.S. compliance enforcement: Guangxi Wuzhou Zhongheng Group (SSE: 600252, Notice Lin 2026-97) received its second China Securities Regulatory Commission (CSRC) warning letter of 2026 ([2026] No. 23) over RMB 796.80 million in restated distribution revenues and a criminal contract-fraud referral, while Consun Pharmaceutical Group (HKEX: 01681) subsidiary Guangxi Yulin Pharmaceutical was cited in an eight-observation U.S. FDA Form 483 for manufacturing U.S.-bound over-the-counter (OTC) batches inside a decommissioned formulation tank for seven consecutive months.

This weekend deep-dive dissects the clinical mechanisms, trial architectures, and forensic accounting/cGMP records behind both waves of disclosures.

Summary matrix: Nine late-week pipeline, generic, and compliance disclosures (Nov 18–21, 2026)

Company (Ticker) Asset / Facility & Filing Code Modality / Regulatory Category Core Clinical or Enforcement Metric Next Evidence Trigger
Jiangsu Hengrui (600276.SS / 01276.HK) HRS-4729 (NCT06762600 Ph1 MAD / NCT07660848 Ph2) Once-weekly SC GLP-1/GIP/GCG triple receptor agonist Week 12 mean MRI-PDFF liver fat drop -81.0% at 8 mg (vs. -41.0% placebo) in n=34 MASLD + obesity subgroup; up to 100% <5% liver fat normalization; weight -9.7% to -16.6% Phase 2 MASH (NCT07660848) biopsy and MRI-PDFF readout
Jiangsu Hengrui (600276.SS / 01276.HK) herombopag olamine (Hengqu) (Lin 2026-182, CXHS2600158) Oral non-peptide TPO-R agonist (5th indication sNDA) Phase 3 SHR8735-302 (n=127, 21 China centers) met primary endpoint in CLD thrombocytopenia prior to elective invasive procedures; cumulative R&D RMB 668.20m NMPA approval decision (2027) vs. avatrombopag (Doptelet) and lusutrombopag (Mulpleta)
Hybio Pharma (300199.SZ) & Qilu Pharma HY3003 Injection (2026-077, 2026LP03570–03575) & QLS7402 (NCT07950462) Once-weekly SC GLP-1R/GIPR/GCGR triple agonist (HY3003) & obesity biologic (QLS7402) 6 NMPA IND approvals (CXHL2601095–1100) for HY3003 weekly SC weight management (joining active U.S. FDA IND + China oral tablet IND); Qilu registers 140-patient Ph1 for QLS7402 Phase 1 human dosing and weight-loss readouts for weekly SC and oral HY3003
Changchun High-Tech / GenSci (000661.SZ) GenSci161 Injection (2026-106, CXSL2601287 & CXSL2601288) Class 1 fully human IgG1 bispecific antibody targeting IL-1α + IL-1β NMPA accepted 6th & 7th IND applications in pyoderma gangrenosum (PG) and CAPS (FCAS/MWS/NOMID), expanding beyond EM, HS (U.S. + China IND), NIU, CTD-ILD, and RP 60-working-day CDE implied IND clearance (~Feb 2027) and Phase 1/2 rare-disease basket data
Huadong Medicine (000963.SZ) HDM4002 Injection (2026-064, 2026LP03558 / CXSL2600971) Class 1 bispecific antibody targeting CFB + MASP-2 NMPA approved Phase 1 IND in adult primary IgA nephropathy (IgAN) to dual-block alternative (CFB) and lectin (MASP-2) complement pathways First-in-human Phase 1 dosing and 24-hour UPCR / eGFR biomarker data
Simcere Pharma (02096.HK) SIM0712 Capsules (Nov 16–20 disclosure) Oral CRBN-recruiting STAT6 PROTAC degrader NMPA approved IND for atopic dermatitis (AD); selectively binds STAT6 SH2 domain (sparing STAT1/STAT5) to block IL-4 and IL-13 Type 2 inflammation Phase 1 healthy-volunteer and AD patient STAT6 degradation kinetics
Shenyang Xingqi (300573.SZ) SQ-25042 Intravitreal Solution (2026-070, 2026LP03584–03586) Class 1 fusion-protein intravitreal biologic Simultaneous NMPA IND approvals across nAMD (LP03584), DME (LP03585), and RVO macular edema (LP03586) Phase 1 intravitreal dosing and durability intervals vs. faricimab / aflibercept
Guangxi Wuzhou Zhongheng (600252.SS) Subsidiary Guangtou Pharma & Group (Lin 2026-97 / Lin 2026-58) CSRC Guangxi Bureau Warning Letter [2026] No. 23 (Nov 20, 2026) Cited for 2023–2025 asset-impairment & revenue errors: RMB 704.14m gross-to-net cut + RMB 92.66m reversal on 5 disputed/criminal-referred distribution clients Nanning PSB criminal fraud investigation outcome & FY2026 audit opinion
Consun (01681.HK) / Guangxi Yulin Pharma & Daiichi Sankyo EU Yulin OTC Plant (8-item FDA 483) & Daiichi EU Plant (3-item FDA 483) U.S. FDA cGMP inspection enforcement (21 CFR Part 211) Yulin: 7 months of U.S. OTC production in red-tagged Tank #4, release without active % assay, QC raw data deletion, no API vendor audits since 2016; Daiichi EU: uncontrolled Empower manual integration Potential FDA Warning Letter or Import Alert 66-40 for Guangxi Yulin Pharmaceutical

1. Metabolic and liver-hematology expansion: Hengrui’s HRS-4729, herombopag, and Hybio’s HY3003

HRS-4729 delivers up to 81.0% Week 12 liver defatting at AASLD 2026

Following our earlier coverage of Boehringer Ingelheim’s survodutide, Novo Nordisk’s semaglutide, and Alnylam’s ALN-CIDEB at AASLD 2026 and Hengrui’s HRS-5635 hepatitis B readout, Hengrui released the full post-hoc subgroup dataset from the oral presentation of its once-weekly subcutaneous GLP-1/GIP/GCG triple receptor agonist HRS-4729 (first-in-human Phase 1 trial NCT06762600, led by Professor Wen Qing and presented by Director He Kun of Jinan Central Hospital).

While GLP-1 and GIP agonism reduce hepatic lipid influx indirectly through systemic weight loss and insulin sensitization, direct activation of hepatic glucagon (GCG) receptors stimulates mitochondrial β-oxidation and suppresses de novo lipogenesis inside hepatocytes. In the multiple-ascending-dose (MAD) cohort of NCT06762600, 48 overweight or obese adults (aged 18–55, BMI 28–40 kg/m²) were randomized to 12 weeks of once-weekly subcutaneous HRS-4729 (1 mg fixed dose, or titrated to target doses of 4 mg, 8 mg, or 12 mg) or placebo. Among the 34 participants with baseline metabolic dysfunction-associated steatotic liver disease (MASLD, defined as magnetic resonance imaging proton density fat fraction [MRI-PDFF] >= 5%):

  • Dose-dependent relative liver fat reduction: At Week 12, mean percentage change from baseline in MRI-PDFF liver fat ranged from -41.0% to -81.0% across HRS-4729 dose cohorts, peaking at -81.0% in the 8 mg group compared with -41.0% in the placebo group (the 12 mg cohort entered with a lower mean baseline liver fat of 8.5%, creating a floor effect).
  • Higher baseline steatosis yielded deeper clearance: Among participants with baseline MRI-PDFF >= 8% and >= 10%, maximum mean relative liver fat reductions reached 82.6% and 89.8%, respectively.
  • Complete steatosis resolution (<5% liver fat): Across the 4 mg, 8 mg, and 12 mg titrated cohorts, the proportion of participants achieving  ≥ 30%,  ≥ 50%, and  ≥ 70% relative liver fat reductions reached up to 100%, and up to 100% of treated participants normalized absolute hepatic fat content below the 5% radiographic steatosis threshold.
  • Anthropometric and safety profile: Over the same 12-week window, HRS-4729 reduced mean body weight by -9.7% to -16.6% (versus -4.8% for placebo) and shrank waist circumference by -8.7 to -14.8 cm (versus -6.7 cm for placebo), alongside reductions in triglycerides, total cholesterol, and LDL-C. All treatment-emergent adverse events (TEAEs) were mild to moderate (predominantly gastrointestinal nausea and vomiting), with zero serious adverse events (SAEs) and zero treatment discontinuations. Hengrui is already evaluating HRS-4729 in a dedicated Phase 2 metabolic dysfunction-associated steatohepatitis (MASH) trial (NCT07660848).

Meanwhile, on November 20, Hybio Pharmaceutical (300199.SZ, Notice 2026-077) received six NMPA clinical trial approval notices (2026LP03570 through 2026LP03575; acceptance numbers CXHL2601095–CXHL2601100) for its own once-weekly subcutaneous GLP-1R/GIPR/GCGR triple agonist HY3003 injection in adult weight management. Hybio is pursuing a three-formulation strategy for HY3003—combining the newly cleared China weekly injection (which already holds an active U.S. FDA IND), a once-daily oral tablet (China IND accepted), and a preclinical monthly extended-release depot—claiming superior weight loss at equimolar doses in diet-induced obese (DIO) mice over both dual agonist tirzepatide and triple agonist retatrutide.

Herombopag (CXHS2600158) targets the peri-procedural CLD thrombocytopenia market

In a separate statutory filing on November 21 (Lin 2026-182), Hengrui announced that the NMPA accepted a supplemental New Drug Application (sNDA, CXHS2600158) for its oral non-peptide thrombopoietin receptor (TPO-R) agonist herombopag olamine (Hengqu) in adults with chronic liver disease (CLD)-associated thrombocytopenia scheduled to undergo elective invasive procedures (including diagnostic procedures).

Backed by RMB 668.20 million in cumulative R&D investment, the filing rests on the multicenter, randomized, double-blind, placebo-controlled Phase 3 SHR8735-302 trial (n=127 across 21 Chinese hospitals led by Professor Zhou Jian at Fudan University Zhongshan Hospital), which met its primary efficacy endpoint in August 2026 by reducing the need for peri-procedural platelet transfusions. Two commercial and clinical details stand out in the filing:

  1. Unifying five TPO-R indications under one patented Class 1 tablet: Herombopag is already approved in China across four hematology and oncology indications—chronic primary immune thrombocytopenia (ITP, adults and children  ≥ 6 years, where it will now compete with HUTCHMED’s newly approved SYK inhibitor sovleplenib / SYVIK), immunosuppressant-refractory severe aplastic anemia (SAA), first-line SAA ( ≥ 15 years) combined with immunosuppressive therapy, and chemotherapy-induced thrombocytopenia (CTIT) in solid tumors. Adding peri-procedural CLD allows Hengrui to challenge Fosun Pharma (600196.SS / 02196.HK) and AkaRx’s avatrombopag (Doptelet) and Shionogi / Eddingpharm’s lusutrombopag (Mulpleta)—a global class that generated $2.222 billion in 2025 sales according to EvaluatePharma data cited in the filing.
  2. Explicit portal vein thrombosis (PVT) label guardrail: Because up to 78% of cirrhotic patients suffer from thrombocytopenia alongside sluggish portal venous flow, chronic TPO-R over-stimulation risks portal vein thrombosis. Hengrui’s proposed indication text explicitly mandates: “Except for application scenarios within the scope of the indication, CLD patients must not take this product to restore normal platelet counts.”

2. Dual-pathway autoimmune, renal, and retinal biologics: GenSci, Huadong, Simcere, and Xingqi

Four additional IND clearances and acceptances between November 18 and November 21 highlight how Chinese R&D teams are moving from single-target “me-too” antibodies to bispecific pathway blockade and targeted protein degradation (PROTAC) in non-oncology indications:

  • Changchun High-Tech / GenSci (000661.SZ, Notice 2026-106) — GenSci161 (IL-1α + IL-1β bispecific IgG1) reaches seven autoinflammatory indications: On November 21, NMPA accepted two new IND filings for GenSci161 in pyoderma gangrenosum (PG, CXSL2601287)—a rare neutrophilic ulcerative dermatosis (3–10 cases per million/year, where only adalimumab in Japan holds a specific approval globally and zero drugs are approved in China)—and cryopyrin-associated periodic syndromes (CAPS, CXSL2601288), an NLRP3 gain-of-function inflammasomopathy (2.7–5.5 per million prevalence spanning FCAS, Muckle-Wells syndrome [MWS], and NOMID/CINCA). Unlike Novartis’s (SIX: NOVN) canakinumab (Ilaris), which neutralizes only IL-1β, GenSci161 simultaneously neutralizes both IL-1α (released as a damage-associated alarmin from necrotic epidermal and endothelial cells) and IL-1β. GenSci has now amassed seven IND filings for GenSci161—with China INDs already approved in endometriosis (EM), hidradenitis suppurativa (HS), non-infectious uveitis (NIU), and connective tissue disease-associated interstitial lung disease (CTD-ILD), a U.S. FDA IND approved in HS, and a China IND accepted in recurrent pericarditis (RP)—building a rare immunology franchise to diversify Changchun High-Tech beyond somatropin growth hormone.
  • Huadong Medicine (000963.SZ, Notice 2026-064) — HDM4002 (CFB × MASP-2 bispecific antibody) in IgA nephropathy: On November 18, wholly-owned subsidiary Zhongmei Huadong received NMPA Phase 1 IND approval (2026LP03558, CXSL2600971) for HDM4002 in adult primary IgA nephropathy (IgAN). Under the “Four-Hit” pathogenesis of IgAN, mesangial deposition of galactose-deficient IgA1 (Gd-IgA1) immune complexes activates both the complement alternative pathway (driven by Complement Factor B [CFB]) and the lectin pathway (driven by MASP-2). While single-pathway agents such as Novartis’s oral CFB inhibitor iptacopan (Fabhalta) or Omeros’s anti-MASP-2 antibody narsoplimab leave the parallel cascade unblocked, HDM4002 is engineered to clamp both the initiation (MASP-2) and amplification (CFB) loops in a single bispecific molecule.
  • Simcere Pharmaceutical (02096.HK) — SIM0712 (oral STAT6 PROTAC degrader) in atopic dermatitis: Simcere secured China IND clearance for SIM0712, an oral heterobifunctional PROTAC that binds the SH2 domain of signal transducer and activator of transcription 6 (STAT6) and recruits the CRBN E3 ubiquitin ligase to degrade STAT6 via the ubiquitin-proteasome system (while sparing STAT1 and STAT5). Because both IL-4 and IL-13 receptors signal obligately through STAT6 to drive Type 2 inflammation, IgE class switching, and epidermal barrier disruption, oral STAT6 degradation aims to replicate the dual IL-4Rα blockade of Sanofi and Regeneron’s injectable dupilumab (Dupixent) in a once-daily capsule.
  • Shenyang Xingqi Ophthalmic (300573.SZ, Notice 2026-070) — SQ-25042 fusion-protein intravitreal injection: On November 20, Xingqi received three simultaneous NMPA IND approvals for Class 1 fusion protein SQ-25042 across neovascular age-related macular degeneration (nAMD, 2026LP03584), diabetic macular edema (DME, 2026LP03585), and macular edema secondary to retinal vein occlusion (RVO, 2026LP03586). Just one week after Zhaoke Ophthalmology (06622.HK) won NMPA approval for its nightly 0.05% cyclosporine ophthalmic gel Jingyouling against Xingqi’s daytime Zirun, SQ-25042 marks Xingqi’s first expansion from anterior-segment topical drops into posterior-segment retinal biologics.
  • Export API & domestic generic clearances (600488.SS, 600521.SS, 688799.SS): Rounding out the week’s statutory filings, Tianjin Tianyao Pharmaceuticals (SSE: 600488, Notice 2026-076) received a U.S. FDA Drug Master File (DMF) First Adequate Letter (DMF #033893, submitted September 2019; RMB 3.00 million R&D spend) for corticosteroid API betamethasone ($835 million global single-agent formulation market in 2025 per IQVIA); Zhejiang Huahai Pharmaceutical (SSE: 600521, Notice Lin 2026-119) won Class 3 generic approval (Guoyao Zhunzi H20266613; RMB 4.24 million R&D spend) for postoperative analgesic ketorolac tromethamine injection (1 mL:30 mg; RMB 88 million 1H 2026 China hospital sales); and Hunan Warrant Pharmaceutical (SSE: 688799, Notice 2026-070) won Class 4 generic approval (Guoyao Zhunzi H20266646, CYHS2501454) for gastric mucosal protectant teprenone capsules (50 mg).

3. Dual Guangxi compliance crackdown: Zhongheng’s RMB 796.8m revenue reversal and Yulin Pharma’s 8-item FDA Form 483

In sharp contrast to the clinical pipeline milestones above, two established pharmaceutical manufacturers headquartered in Guangxi Province—state-backed Guangxi Wuzhou Zhongheng Group (600252.SS, maker of Xueshuantong freeze-dried panax notoginseng saponins) and Consun Pharmaceutical (01681.HK) subsidiary Guangxi Yulin Pharmaceutical (maker of Zhenggushui and Shiduqing)—became the focus of domestic securities and U.S. FDA cGMP enforcement on November 20 and 21.

CSRC Guangxi Bureau Warning Letter [2026] No. 23 at Zhongheng Group (600252.SS): Gross-to-net inflation and suspected criminal distribution fraud

On November 21 (Lin 2026-97), Zhongheng Group disclosed that on November 20 it received Administrative Regulatory Measure Decision [2026] No. 23 from the CSRC Guangxi Bureau, issuing a formal Warning Letter (Jingshihan) and Integrity Archive record against the company, current Chairman Yang Jinhai, and former CFO Ge Hui for improper asset-impairment accounting and inaccurate revenue-recognition methods across 2023, 2024, and 2025.

Cross-referencing Lin 2026-97 with Zhongheng’s prior restatement filing (1225022354.PDF, March 21, 2026) and its Shanghai Stock Exchange Annual Report Inquiry Reply (Lin 2026-58, July 8, 2026) exposes the exact mechanics of how traditional Chinese medicine (TCM) companies inflate top-line distribution revenue when core injectable hospital volumes come under procurement pressure:

  1. RMB 704.14 million in improper gross-method (Zong'efa) revenue booking: Under China Accounting Standard No. 14 (CAS 14 Article 34), a distributor may book full gross revenue (principal basis) only if it takes physical control, inventory risk, and pricing authority before transferring goods; otherwise, it must book only the net agency fee (net basis). Between 2023 and 3Q 2025, Zhongheng booked API, ejiao (donkey-hide gelatin), non-stocked sanqi/dilong herbal trades, and drop-shipped health foods, household chemicals, and medical devices—where suppliers shipped directly to customers without Zhongheng handling logistics or retaining bills of lading—on a 100% gross basis, including trades with overlapping customer-supplier counterparties. Following regulatory scrutiny, Zhongheng was forced to restate those trades to a net basis, wiping out RMB 127.89 million of reported revenue in FY2023, RMB 166.06 million in FY2024, and RMB 410.18 million in 9M 2025 (RMB 704.14 million cumulative).
  2. RMB 92.66 million in reversed wholesale trades referred to Economic Crime Police (Jingzhen): Even more damaging, Zhongheng’s distribution subsidiary Guangtou Pharmaceutical (Guangxi Investment Pharmaceutical) booked RMB 92.66 million in 9M 2025 gross pharmaceutical sales (and RMB 87.22 million in unpaid receivables) across five regional wholesalers all introduced by the exact same intermediary:
    • Guangxi Qucaotang Pharmaceutical Logistics: RMB 32.57 million net revenue (RMB 36.80m tax-inclusive; RMB 24.73m unpaid balance; sourced from Guangxi Jointown);
    • Guangxi Haixing Pharmaceutical (formerly Guangxi Neptunus Galaxy): RMB 17.73 million (RMB 19.34m unpaid; sourced from Guangxi Jointown);
    • Guangxi Du'an Jianxing Pharmaceutical: RMB 16.75 million (RMB 18.92m unpaid; circularly sourced from Qucaotang, Fudi Huaren, Sinopharm Guangxi, and Haixing);
    • Guangxi Fudi Huaren Pharmaceutical: RMB 15.24 million (RMB 12.03m unpaid); and
    • Yunnan Pharmaceutical Technology Development: RMB 10.38 million (RMB 10.19m unpaid).

When Qucaotang defaulted in 2025 and Guangtou Pharmaceutical filed a civil collection lawsuit, both first- and second-instance courts dismissed the civil suit on grounds of suspected criminal contract fraud and ordered the case transferred on May 12, 2026 to the Nanning Public Security Bureau Jiangnan Branch Economic Crime Investigation Brigade—forcing Zhongheng to reverse the entire RMB 92.66 million in revenue (and RMB 1.84 million in net profit) and triggering two successive CSRC warning letters ([2026] No. 5 in June and [2026] No. 23 on November 20).

U.S. FDA Form 483 at Guangxi Yulin Pharmaceutical (8 Observations) and Daiichi Sankyo Europe (3 Observations)

While CSRC policed financial reporting in Wuzhou, newly released U.S. FDA Form 483 inspection reports highlighted quality-system breakdowns at Guangxi Yulin Pharmaceutical Group (a subsidiary of Hong Kong-listed Consun Pharmaceutical 01681.HK; inspected March 17–21, 2025, with an 8-observation Form 483 issued to Chairman Guo Guorong) and Daiichi Sankyo (TSE: 4568) Europe’s formulation plant (inspected July 14–18, 2025; 5-page amended Form 483 with 3 observations):

Facility & Inspection Window Cited 21 CFR Part 211 / cGMP Observation Operational & Regulatory Detail Verified in Form 483
Guangxi Yulin Pharmaceutical (Consun 01681.HK, Mar 17–21, 2025; 8 observations) Obs. 5 — Continued Production in Decommissioned Tank (211.100(b)) After receiving a formal notice to stop using Formulation Tank #4, the plant failed to open a deviation or suitability evaluation and continued manufacturing batches in Tank #4 for 7 consecutive months until replacement; 100% of those batches were exported to the U.S.
Guangxi Yulin Pharmaceutical Obs. 1 & Obs. 3 — OTC Release & Stability Without Assay (211.165(a) / 211.166(a)) Exported OTC drug batches were released to the U.S. market without testing active-ingredient concentration against labeled % specs (reporting mg/mL without verifying label %), and lacked any written stability-testing protocol or stability-indicating assay
Guangxi Yulin Pharmaceutical Obs. 2 — Data Integrity & Missing Audit Trails (211.160(b)) Analytical laboratory software lacked electronic audit trails, allowing QC personnel to freely delete raw analytical data; test methods were unvalidated and internal standards conflicted with the Chinese Pharmacopoeia
Guangxi Yulin Pharmaceutical Obs. 4, 6, 7 & 8 — 2016 Vendor Audits, Cleaning & Yield (211.84 / 211.67 / 211.125) Most recent API supplier audit record dated back to 2016 (9-year gap) with SOP edits bypassing change control (Obs. 7); unvalidated batch-size yield limits (Obs. 4), unvalidated cleaning hold times (Obs. 6), and missing packaging label reconciliation (Obs. 8)
Daiichi Sankyo Europe Formulation Plant (July 14–18, 2025; 3 observations) Obs. 1, 2 & 3 — Uncontrolled Empower Manual Integration & OOS Invalidation Laboratory lacked an SOP governing Empower chromatography manual integration, with widespread manual peak re-integration performed without justification, authorization, or audit-trail review (Obs. 1); two content-uniformity OOS results invalidated without analyst interviews (Obs. 2); visible material residue on gaskets and chipped tablet punches on equipment logged as cleaned (Obs. 3)

For global supply-chain and quality teams, Yulin Pharmaceutical’s eight-item Form 483—combining seven months of production in a red-tagged vessel with raw data deletion and a nine-year gap in API vendor audits—carries a high probability of escalating into an FDA Import Alert (66-40, detention without physical examination of unapproved/cGMP-deficient drugs) or a formal Warning Letter in late 2026 or early 2027.